Active Ingredient(s): Dinutuximab
FDA Approved: * March 10, 2015
Pharm Company: * UNITED THERAP
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Unituxin Overview

Dinutuximab (Ch14.18, tradename Unituxin) and Dinutuximab beta (tradename Qarziba) are monoclonal antibodies used as a second-line treatment for children with high-risk neuroblastoma. Each antibody is made of both mouse and human components and targets glycolipid GD2, expressed on neuroblastoma cells and on normal cells of neuroectodermal origin, including the central nervous system and peripheral nerves. They differ in that dinutuximab is manufactured using mouse cells, and dinutuximab bet...

Read more Unituxin Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Dinutuximab

Recent Unituxin Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 17.5mg/5ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Unituxin: (1 result)

Sorted by National Drug Code
  • 66302-014 Unituxin 3.5 mg/ml Intravenous Injection by United Therapeutics Corp.

Other drugs which contain Dinutuximab or a similar ingredient: (1 result)